Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02681809 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
A Phase 2 study, sponsored by ThromboGenics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT02681809 is a Phase 2 study that was terminated before completion, run by ThromboGenics. The registered enrollment target is 48 participants.
The verdict
NCT02681809, a Phase 2 study, was terminated before completion, sponsored by ThromboGenics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of up to 3 intravitreal injections of ocriplasmin (0.0625mg or 0.125mg), in subjects with moderate to very severe non-proliferative diabetic retinopathy (NPDR), to induce total posterior vitreous detachment (PVD) in order to reduce the risk of disease progression to proliferative diabetic retinopathy (PDR).
Interventions
- DRUG Sham injection
- DRUG ocriplasmin 0.0625mg
- DRUG ocriplasmin 0.125mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2015-12 |
| Est. Completion | 2019-11-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02681809
The ClinicalTrials.gov registry entry for NCT02681809 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ThromboGenics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sham injection is the first listed.
NCT02681809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02681809 about?
NCT02681809 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR". The purpose of this study is to assess the efficacy and safety of up to 3 intravitreal injections of ocriplasmin (0.0625mg or 0.125mg), in subjects with moderate to very severe non-proliferative diabetic retinopathy (NPDR), to induce total posterior vitreous detachment (PVD) in order to reduce the r...
What is the current status of trial NCT02681809?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2015-12. Estimated completion is 2019-11-18.
What interventions are being tested in trial NCT02681809?
The interventions under investigation include: Sham injection (DRUG), ocriplasmin 0.0625mg (DRUG), ocriplasmin 0.125mg (DRUG).
Who is sponsoring clinical trial NCT02681809?
This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.